GSK (LSE: GSK) subsidiary Sierra Oncology has returned rights for oncology candidate SRA737 to the CRT Pioneer Fund (CPF), a joint initiative between commercialization and development company Cancer Research Technology and the European Investment Fund.
The move sent shares in Sareum Holdings (AIM: SAR) tumbling. The UK biotech, which is developing next generation kinase inhibitors for autoimmune disease and cancer, was trading more than 20% lower at lunchtime on Wednesday.
"We continue to believe that SRA737 has great potential in several oncology applications"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze